Collaboration will expand international research, quality improvement opportunities
WASHINGTON, Nov. 5, 2015 /PRNewswire-USNewswire/ -- The American College of Cardiology (ACC) is joining with the National Heart Centre Singapore (NHCS) to create a global diabetes registry that will support diabetes and cardiometabolic research and provide new opportunities to improve the quality of care provided to patients around the world.
Diabetes mellitus is a complex, chronic disease with increasing prevalence rates affecting 382 million people worldwide, a number that is expected to rise to 592 million by 2035. One in three Americans is expected to develop diabetes in their lifetime. More than 60 percent of the world's diabetic population is located in Asia.
The joint effort will bring the newly created NHCS Asian Diabetes Outcomes Registry, known as ADORE, into partnership with the Diabetes Collaborative Registry, expanding the ACC-led registry into 12 countries across Asia to create the first global, cross-specialty clinical diabetes registry.
"This collaboration has the potential to generate unique, insightful, high-impact research that will likely affect the lives of millions of people," said Mikhail N. Kosiborod, MD, FACC, cardiologist and professor of medicine at Saint Luke's Mid America Heart Institute and steering committee chair of the Diabetes Collaborative Registry. "Expanding the Diabetes Collaborative Registry into Asia will also expand our ability to track and improve the quality of diabetes and cardiometabolic care for patients, spanning the spectrum of the disease process in primary and specialty care settings – and now also spanning the globe."
The Diabetes Collaborative Registry, which has grown even more rapidly than anticipated since its inception in 2014 reflecting a strong need to gather and share information about diabetes care, includes more than 250 cross-specialty practice entities with more than 1,000 practice locations and 2,800 providers across 36 states in the U.S.
ADORE is a real-world, prospective, longitudinal, investigator-led registry that will collect comprehensive data for type 2 diabetes treatment patterns and outcomes throughout Asia with a goal to create a network of sites with thousands of patients in China, South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, the Philippines, Hong Kong, India, Vietnam and Sri Lanka.
Data from ADORE will provide insight into real-world treatment patterns in Asian patients, describe effectiveness and safety for key treatment classes and product types in more diverse populations, and will help quantify real-world treatment adherence. It will also provide information about major complications of diabetes and understanding of treatment outcomes in sociocultural subgroups.
"Partnering with the Diabetes Collaborative Registry will expand the impact of ADORE as we combine our expertise and align our data collection to support transnational, comparative, and collaborative diabetes and cardiometabolic research," said Associate Professor Carolyn Lam, MBBS, FACC, senior consultant with the department of cardiology at NHCS and ADORE principal investigator. Professor Lam is also clinician scientist of the cardiovascular sciences academic clinical programme at the SingHealth Duke-NUS Academic Medical Centre.
ACC Executive Vice President of Science, Education, Quality and Publishing William J. Oetgen, MD, MBA, FACC, said the ACC is seeking additional supporters and partners to join the collaboration.
"Our open, innovative model for collaboration embodies, in the truest sense, a real-world diabetes collaborative, where each partner shares expertise to accelerate our collective vision to transform the future of diabetes care," Oetgen said. "Through partnerships we can lead the way to drive meaningful change that will have a lasting impact."
The Diabetes Collaborative Registry® is the first, real-world, interdisciplinary, quality improvement-driven, clinical data registry aimed at tracking and improving the quality of diabetes and cardiometabolic care across the primary and specialty care continuum. Led by the American College of Cardiology, in partnership with the American Diabetes Association, the American College of Physicians, the American Association of Clinical Endocrinologists and the Joslin Diabetes Center, the Diabetes Collaborative Registry is a big data collaboration that allows for a longitudinal study of diabetes across all stages of the disease—including presentation, progression, management and outcomes—even as patients receive treatment from multidisciplinary care teams. The mission of the Diabetes Collaborative Registry is to generate data-driven, evidence-based insights and solutions that will transform the future of personalized, high quality care and outcomes for people across the globe. The registry is sponsored by AstraZeneca (Founding Sponsor) and Boehringer Ingelheim Pharmaceuticals, Inc. For more information, visit TheDiabetesRegistry.org.
The American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit acc.org.
The National Heart Centre Singapore (NHCS) is a 185-bed national and regional referral centre for cardiovascular diseases. The Centre is the largest public cardiovascular care provider in Singapore. NHCS is dedicated to providing optimal care for patients through the three core pillars of patient care, education and training, and research. The Centre partnered with the Duke-NUS to set up the National Heart Research Institute Singapore, with key research themes in heart function and genetics, metabolic heart disease and imaging, and regenerative medicine. For more information, visit nhcs.com.sg.
SOURCE American College of Cardiology